Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

Core Insights - Cellectis is hosting an R&D Day to present full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) [1] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using a pioneering gene-editing platform [2] - The company employs an allogeneic approach for CAR T immunotherapies, aiming to create off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment [2] - Cellectis has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that control the entire cell and gene therapy value chain [2] - The company is headquartered in Paris, France, with additional locations in New York and Raleigh, NC, and is listed on both Nasdaq and Euronext Growth [2]